221 results on '"Fast, Patricia E."'
Search Results
2. HIV immunoprophylaxis: preparing the pathway from proof of concept to policy decision and use
3. Cost-effectiveness of broadly neutralizing antibodies for infant HIV prophylaxis in settings with high HIV burdens: a simulation modeling study
4. Use of propensity score matching to create counterfactual group to assess potential HIV prevention interventions
5. Involvement of African men and transgender women who have sex with men in HIV research: progress, but much more must be done
6. Comparison of HIV Risk Behaviors Between Clinical Trials and Observational Cohorts in Uganda
7. rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment
8. A Phase 1 Study of 4 Live, Recombinant Human Cytomegalovirus Towne/Toledo Chimera Vaccines in Cytomegalovirus-Seronegative Men
9. Comparison of retention in observational cohorts and nested simulated HIV vaccine efficacy trials in the key populations in Uganda
10. Publisher Correction: Use of reliable contraceptives and its correlates among women participating in Simulated HIV vaccine efficacy trials in key-populations in Uganda
11. Status of vaccine research and development of vaccines for HIV-1
12. Comparison of HIV incidence estimated in clinical trial and observational cohort settings in a high risk fishing population in Uganda: Implications for sample size estimates
13. Response to: 'Inclusion as Illusion: Erasing Transgender Women in Research with MSM'
14. Use of reliable contraceptives and its correlates among women participating in Simulated HIV vaccine efficacy trials in key-populations in Uganda
15. Region-specific laboratory reference intervals are important: A systematic review of the data from Africa
16. Differences in acute retroviral syndrome by HIV-1 subtype in a multicentre cohort study in Africa
17. Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention
18. Clinical Considerations in Vaccine Trials with Special Reference to Candidate HIV Vaccines
19. Comparison of the Safety, Vaccine Virus Shedding, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A and B, Live Cold-Adapted, Administered to Human Immunodeficiency Virus (HIV)-Infected and Non-HIV-Infected Adults
20. Immunization with Envelope MN rgp120 Vaccine in Human Immunodeficiency Virus-Infected Pregnant Women
21. Analysis of Intercurrent Human Immunodeficiency Virus Type 1 Infections in Phase I and II Trials of Candidate AIDS Vaccines
22. A Dose-Ranging Study of a Prototype Synthetic HIV- $1_{MN}$ V3 Branched Peptide Vaccine
23. Long-term follow-up of study participants from prophylactic HIV vaccine clinical trials in Africa
24. Disease progression by infecting HIV-1 subtype in a seroconverter cohort in sub-Saharan Africa
25. The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines
26. The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines
27. Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines
28. Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial
29. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers
30. Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events
31. Cohort Profile: IAVI’s HIV epidemiology and early infection cohort studies in Africa to support vaccine discovery
32. The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines
33. The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines
34. Specificity of CD8+ T-Cell Responses Following Vaccination with Conserved Regions of HIV-1 in Nairobi, Kenya
35. Acceptability and tolerability of repeated intramuscular electroporation of Multi-antigenic HIV (HIVMAG) DNA vaccine among healthy African participants in a phase 1 randomized controlled trial
36. Comparison of retention in observational cohorts and nested Simulated HIV Vaccine Efficacy Trials in the Key populations in Uganda
37. HIV vaccines: current status worldwide and in Africa
38. Clinical Considerations in Vaccine Trials with Special Reference to Candidate HIV Vaccines
39. Referee report. For: Clues to finding correlates of risk/protection for HIV-1 vaccines [version 2; referees: 1 approved with reservations]
40. Comparison of retention in observational cohorts and nested Simulated HIV Vaccine Efficacy Trials in the Key populations in Uganda
41. Control of the HIV-1 Load Varies by Viral Subtype in a Large Cohort of African Adults With Incident HIV-1 Infection
42. Simulated vaccine efficacy trials to estimate HIV incidence for actual vaccine clinical trials in key populations in Uganda
43. Safety and Immunogenicity of a Candidate HIV-1 Vaccine in Healthy Adults: Recombinant Glycoprotein (rgp) 120: A Randomized, Double-Blind Trial
44. Human trials of experimental AIDS vaccines
45. HIV vaccine trials: some design issues including sample size calculation
46. Referee report. For: Clues to finding correlates of risk/protection for HIV-1 vaccines [version 1; referees: 1 not approved]
47. Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control
48. Prediction of extended high viremia among newly HIV-1-infected persons in sub-Saharan Africa
49. Simulated Vaccine Efficacy Trials to Estimate HIV Incidence for Actual Vaccine Clinical Trials in Key Populations in Uganda
50. Augmentation of Human Immunodeficiency Virus Type 1 Neutralizing Antibody by Priming with gpl60 Recombinant Vaccinia and Boosting with rgpl60 in Vaccinia-Naive Adults
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.